Residency · Residency · Chronic Pain Management

Pediatric Chronic Pain

Introduction

Chronic pain in children and adolescents affects 20-35% of youth worldwide, with functional disability ranging from mild school absences to complete social withdrawal. The developing nervous system processes pain differently from adults, and pediatric chronic pain demands an understanding of developmental neurobiology, age-appropriate assessment, and family-centered treatment models. Untreated pediatric chronic pain predicts adult chronic pain, disability, and psychiatric morbidity, making early intervention critical.

Developmental Neurobiology of Pain

Neonatal and Infant Pain Processing

Nociceptive pathways are functional by 24 weeks gestational age, and neonates demonstrate robust pain responses. The neonatal spinal cord exhibits lower thresholds for activation and exaggerated wind-up compared to adults. Descending inhibitory pathways from the periaqueductal gray and rostroventral medulla are immature at birth and mature gradually through early childhood. This imbalance between ascending excitatory and descending inhibitory function means that neonates are not insensitive to pain -- they are, if anything, more vulnerable to it. Repeated neonatal pain exposure, such as that experienced during NICU procedures, produces long-term alterations in pain sensitivity and stress-response systems. Early pain experiences create epigenetic modifications in stress-response genes, including those governing the HPA axis and glucocorticoid receptors.

Childhood and Adolescent Development

Central sensitization occurs more readily in the developing nervous system. Myelination of pain-modulatory circuits continues through adolescence. Adolescent brains show heightened emotional reactivity to pain due to the relative immaturity of the prefrontal cortex compared to the limbic system -- the emotional brain matures before the regulatory brain. Puberty-related hormonal changes influence pain processing and contribute to the female predominance of chronic pain that emerges during adolescence. The neuroplasticity of the developing brain is a double-edged sword: it creates vulnerability to chronic pain development but also offers greater opportunity for treatment responsiveness.

<image>Developmental timeline illustration of the pain system from fetal period through adolescence, showing progressive maturation of nociceptive pathways (functional at 24 weeks gestation), ascending pain transmission (myelinating through infancy), descending inhibitory pathways (maturing through childhood into adolescence), and prefrontal cortical modulation (not fully mature until early adulthood), with key vulnerability windows marked for NICU exposure, early childhood adversity, and pubertal transition, and annotations showing how each developmental stage affects pain processing capacity.</image>

Common Functional Pain Syndromes

Functional Abdominal Pain Disorders

Functional abdominal pain (FAP) affects 10-15% of school-age children and encompasses irritable bowel syndrome, functional dyspepsia, and abdominal migraine. The Rome IV criteria define subtypes based on symptom patterns. The proposed mechanism is central sensitization of visceral afferents with visceral hyperalgesia. GI-directed hypnotherapy has shown remarkable results, with 85% improvement rates sustained at 5-year follow-up.

Complex Regional Pain Syndrome (CRPS)

Pediatric CRPS presents most commonly in girls aged 9-15 years, predominantly affecting the lower extremities. The prognosis is significantly better than in adults, with high rates of full resolution when aggressive physical therapy is pursued. Exercise-based rehabilitation, not sympathetic nerve blocks, is the primary treatment. Psychological comorbidity -- particularly anxiety and perfectionism -- is prevalent and requires concurrent treatment.

Musculoskeletal Pain Syndromes

Juvenile fibromyalgia affects 2-6% of adolescents, with diagnostic criteria adapted from adult criteria. Amplified musculoskeletal pain syndrome (AMPS) encompasses a spectrum that includes CRPS and diffuse amplified pain. Hypermobility spectrum disorders and Ehlers-Danlos syndrome frequently present with chronic pain in pediatric populations. Growing pains affect 25-40% of children but are typically self-limited.

Headache Disorders

Chronic migraine (more than 15 headache days per month) affects 1-2% of adolescents. Medication overuse headache is increasingly common with over-the-counter analgesic availability. New daily persistent headache (NDPH) presents unique treatment challenges in the adolescent population.

Pain Assessment Across Development

Pain assessment tools must be matched to developmental stage. Neonates are assessed with the NIPS (Neonatal Infant Pain Scale) or FLACC (Face, Legs, Activity, Cry, Consolability). Preschool-age children (3-6 years) use the Wong-Baker FACES Pain Rating Scale or FLACC. School-age children (7-12 years) can typically use a Numeric Rating Scale (NRS) or the Faces Pain Scale-Revised (FPS-R). Adolescents use the NRS, visual analog scale, or multidimensional tools like the PedsQL and Functional Disability Inventory (FDI). The FDI is a validated measure of pain-related disability in youth and is especially useful for tracking treatment response. Self-report should always be supplemented with parent report and functional assessment, as children may under- or over-report depending on context.

Psychological Approaches

Cognitive-Behavioral Therapy (CBT)

CBT is the first-line psychological treatment for pediatric chronic pain, with strong evidence across multiple pain conditions. It addresses pain catastrophizing, fear-avoidance, and maladaptive coping strategies, incorporating relaxation training, guided imagery, and cognitive restructuring. Typically delivered in 8-12 sessions with concurrent parent sessions, CBT can also be delivered via internet-based programs that expand access for underserved populations.

Acceptance and Commitment Therapy (ACT)

ACT emphasizes psychological flexibility and engagement in valued activities despite pain. It is particularly effective for adolescents who resist the structured cognitive challenging approach of traditional CBT. Its focus on experiential avoidance as a driver of functional disability resonates well with the adolescent experience.

Biofeedback and Neurofeedback

Thermal biofeedback has Grade A evidence for pediatric migraine. Heart rate variability biofeedback teaches autonomic self-regulation. EMG biofeedback is useful for tension-type headache and myofascial pain.

Hypnotherapy

Gut-directed hypnotherapy has the strongest evidence base of any intervention for pediatric functional GI disorders. Hypnotherapy is also effective for procedural pain, headache, and musculoskeletal pain. Children are generally more hypnotically suggestible than adults, making this approach particularly well-suited to the pediatric population.

<image>Illustration of a pediatric interdisciplinary pain rehabilitation program showing a child patient at the center connected to five treatment modalities arranged in a circle: psychology (CBT, ACT, biofeedback with therapist and child practicing relaxation), physical therapy (graded exercise with a therapist guiding stretching and strengthening activities), medical management (physician reviewing medications with parent), school reintegration (teacher and school counselor planning accommodations), and family therapy (family group session addressing parental responses to pain behaviors), with outcome measures shown at the bottom including school attendance, physical function, sleep quality, and mood improvement.</image>

Pharmacotherapy Considerations

General Principles

The "start low, go slow" principle applies, with weight-based dosing adjustments. Many analgesics lack pediatric-specific FDA approval, requiring off-label prescribing with informed consent. Liquid formulations and compounded preparations improve adherence in younger children. Adolescent-specific considerations include adherence challenges, diversion risk, and the need for substance use screening.

Specific Medications

Acetaminophen and ibuprofen are first-line analgesics; aspirin should be avoided under age 18 due to the risk of Reye syndrome. Amitriptyline is the most commonly used agent for pediatric neuropathic pain and headache prophylaxis, started at 0.1 mg/kg at bedtime. Gabapentin is used for neuropathic pain, starting at 5 mg/kg/day and titrating upward, with sedation and behavioral changes as common side effects. Duloxetine is FDA-approved for generalized anxiety disorder in children over 7 years and is used off-label for pain. Opioids are reserved for acute-on-chronic flares, postoperative pain, or palliative care; chronic opioid therapy is strongly discouraged in pediatric chronic non-cancer pain. Topical agents such as lidocaine patches and diclofenac gel offer localized relief with minimal systemic exposure.

Medications to Avoid

Codeine carries an FDA black box warning against use in children under 12 due to the risk of fatal respiratory depression in ultra-rapid CYP2D6 metabolizers. Tramadol is FDA-contraindicated under 12 years, with a warning for ages 12-18 in patients with obesity, OSA, or respiratory compromise. Meperidine has no role in pediatric pain management due to neurotoxic metabolite accumulation.

Family-Centered Interdisciplinary Care

Parental Role in Pediatric Pain

Parental catastrophizing is a stronger predictor of child disability than the child's own pain catastrophizing -- what parents think and do matters enormously. Solicitous parenting behaviors such as excessive attention to pain and removal of normal expectations reinforce disability through operant conditioning. Parent training to promote coping-promoting responses is an essential component of any treatment plan.

Interdisciplinary Program Components

Intensive interdisciplinary pain treatment (IIPT) programs achieve significant functional improvement in 70-80% of participants. A typical program runs 3-4 weeks with daily programming of 6-8 hours per day. Components include physical therapy, occupational therapy, psychology, recreational therapy, school reintegration, and family therapy. School reintegration planning with IEP or 504 accommodations is a critical outcome target. The overarching goal is return to full participation in age-appropriate activities.

<image>Infographic showing the vicious cycle of pediatric chronic pain disability, starting with pain experience leading to fear and avoidance, then school absence and social withdrawal, followed by deconditioning and loss of peer relationships, leading to depression and anxiety, which amplifies pain perception, completing the cycle. Intervention points are marked with green arrows showing where CBT breaks fear-avoidance, physical therapy addresses deconditioning, school reintegration restores social participation, and family therapy modifies reinforcing parental responses.</image>

Clinical Pearls

Codeine is contraindicated in all children under 12 and should be avoided in adolescents; CYP2D6 ultra-rapid metabolizer status creates unpredictable risk of respiratory depression. The most effective treatment for pediatric CRPS is intensive physical and occupational therapy with psychological support, not sympathetic nerve blocks. Parental behavior modification is often more impactful than direct child treatment -- always include parent training in the treatment plan. Pediatric chronic pain is a predictor of adult chronic pain, and early intervention with interdisciplinary care can alter the trajectory. Functional disability, not pain intensity, should be the primary treatment target in pediatric chronic pain management.

References

1. Fisher E, Law E, Dudeney J, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database of Systematic Reviews. 2018;9:CD003968.
2. Hechler T, Kanstrup M, Holley AL, et al. Systematic review on intensive interdisciplinary pain treatment of children with chronic pain. Pediatrics. 2015;136(1):115-127.
3. King S, Chambers CT, Huguet A, et al. The epidemiology of chronic pain in children and adolescents revisited: a systematic review. Pain. 2011;152(12):2729-2738.
4. Walco GA, Dworkin RH, Krane EJ, et al. Neuropathic pain in children: special considerations. Mayo Clinic Proceedings. 2010;85(3 Suppl):S33-S41.

Read this lecture as Markdown